Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. 2014

Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
Brendan M. Weiss, University of Pennsylvania, Philadelphia, PA; Joseph Hebreo, Naval Medical Center San Diego, San Diego, CA; Daniel V. Cordaro, Mark J. Roschewski, Thomas Baker, Kevin C. Abbott, and Stephen W. Olson, Walter Reed National Military Medical Center, Bethesda, MD. brendan.weiss@uphs.upenn.edu.

OBJECTIVE Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. METHODS We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. RESULTS An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/L; P < .001), 4 to 11 years (65.1 v 2.2 mg/L; P < .001), and more than 11 years (4.5 v 0.4 mg/L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). CONCLUSIONS Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years.

UI MeSH Term Description Entries
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
March 2018, Leukemia,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
January 2020, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
June 2015, Journal of cardiovascular translational research,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
November 2003, Clinical chemistry,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
February 2014, Expert review of hematology,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
June 2022, The American journal of medicine,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
January 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
May 1990, The American journal of pathology,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
November 2006, Clinical lymphoma & myeloma,
Brendan M Weiss, and Joseph Hebreo, and Daniel V Cordaro, and Mark J Roschewski, and Thomas P Baker, and Kevin C Abbott, and Stephen W Olson
January 2016, Cancer treatment and research,
Copied contents to your clipboard!